The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|September 1, 2016
Richard Bergström Quits EFPIA
Author(s)Philip Ward
The director general leaves his position at the European Federation of Pharmaceutical Industries and Associations (EFPIA) after five years to pursue “a fresh challenge.”
Advertisement
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced that its director general, Richard Bergström, is leaving the post.
“I am proud to leave EFPIA at a time when we have developed policies that promote innovation and patient access, such as through the focus on outcomes and on adaptive pathways to speed up the development of new medicines. After 15 fantastic years leading industry associations in Sweden and in Brussels, it is time for me to take on a fresh challenge,” he said.
Bergström succeeded Brian Ager as director general on April 1, 2011. He was previously director general of LIF, the Swedish research-based pharmaceutical industry association. He is a pharmacist by trade who worked for almost 20 years in the pharmaceutical industry, before moving to LIF in 2002.
Previously Bergström was chair of EFPIA’s Trust Committee and Task Force on Health Technology Assessment and a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He served on several Swedish government commissions and was vice chairman of the board of the Karolinska Institutet.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5